Chronic Kidney Disease Drugs Market Estimated To Witness High Growth Owing To Increasing Prevalence Of Chronic Kidney Disease

Chronic kidney disease drugs are used to manage symptoms and slow the progression of chronic kidney disease. These drugs mainly include antihypertensives, erythropoiesis-stimulating agents, Vitamin D analogs, phosphate binders, and others. Chronic kidney disease affects a large population worldwide and is a major cause of increased healthcare expenditure. Drugs to manage the condition offer treatment alternatives to slow disease progression and manage associated conditions and symptoms.

The global Chronic Kidney Disease Drugs Market is estimated to be valued at US$ 13,220.0 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The chronic kidney disease drugs market is driven by the increasing prevalence of chronic kidney disease worldwide. As per the 2019 Global Burden of Disease Study, about 1.2 million deaths were attributed to chronic kidney disease in 2019. Genetic factors, diabetes, and hypertension are major risk factors leading to rising disease incidence. Further, launch of new pipeline drugs and therapy alternatives by key players is also expected to support market growth over the forecast period. For instance, AstraZeneca received FDA approval for Farxiga in 2020 for treatment of patients with chronic kidney disease at risk of progression with and without diabetes. However, stringent regulatory landscape and high costs associated with drug development pose challenges to market players.

SWOT Analysis
Strength: The chronic kidney disease drugs market has a wide scope for innovation and development of new drugs and treatment options. The increasing R&D investment and growing clinical trials for better drug therapies are expanding treatment options. Three major players are focusing on developing new drug candidates that can reduce progression of kidney disease and improve treatment outcomes.
Weakness: The high costs associated with drug development and clinical trials are major barriers. Also, the pricing and reimbursement challenges for high-priced drugs limit market growth. The presence of alternative treatment options like dialysis and transplant limits sole dependence on drugs.
Opportunity: The rising geriatric population and increasing prevalence of diabetes and hypertension in developing nations present lucrative growth opportunities. The development of innovative drug delivery systems, combo therapies, and personalized medicine represents major opportunities.
Threats: Patent expirations of blockbuster drugs results in lower revenues for companies. The stringent regulatory approvals and safety concerns over side effects of drugs also pose threats. Increasing adoption of alternative treatment limits sole drug dependence.

Key Takeaways
The global Chronic Kidney Disease Drugs market size is expected to witness high growth, exhibiting CAGR of 4.5% over the forecast period, due to increasing prevalence of diabetes, hypertension, and obesity.

Regional analysis:
North America dominates the global market accounting for over 40% share, owing to the presence of major players, well-established healthcare infrastructure, and higher adoption of advanced treatment options. Asia Pacific region is expected to witness the fastest growth rate, exhibiting a CAGR over 6% during the forecast period. This is attributed to the rising healthcare expenditure, growing awareness about early diagnosis, and increasing patient pool in China and India.

Key players related content:
Key players operating in the Chronic Kidney Disease Drugs market are Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Cal